Computational Biology & Digital Sciences
At Boehringer Ingelheim, we are investing into the power of computational biology and data sciences to accelerate the journey from scientific discoveries to breakthrough therapies.
Search
Oncology Translational Science
Discover how Boehringer Ingelheim leverages translational science to bridge pre-clinical research and clinical development, enhancing patient outcomes in oncology. Learn about our patient-centric strategies, biomarker discovery, and collaborative efforts
Research Institute of Molecular Pathology IMP
Funded primarily by Boehringer Ingelheim and with unconstrained academic freedom, the Research Institute of Molecular Pathology (IMP) is a leading institute for biomedical researchin Vienna, Austria.
Vaccines
Vaccines
Data Science: Revolutionizing research and development with data driven insights
Using data in pharmaceutical research to better address patient needs
Our innovation strategy
Our Innovation Strategy at Boehringer Ingelheim in Research and Development
The Research Process
The Research Process
“My ultimate goal is to cure cancer”
“My ultimate goal is to cure cancer”
Boehringer Ingelheim’s Postdoctoral Program
Boehringer Ingelheim’s postdoctoral program in Regional Center Vienna (RCV) provides scientists with the opportunity to pursue research.
Small Molecule Drug Discovery
Boehringer Ingelheim scientists continue to expand the horizons of what small molecule drugs can achieve.
Feline diabetes detect it, treat it and get your life back
Feline diabetes: What are the symptoms of diabetes in cats, and how do you manage this chronic disease?
Data Privacy-video surveillance at Boehringer Ingelheim
Data Protection Notice for video surveillance
Biotherapeutics Discovery
Our committed team of scientists are using all their experience and knowledge to forge new research paths, engineer new molecules and do whatever it takes to make sure that no patient is left behind in our search for the next breakthrough.
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Health, Safety & Environment
Suppliers aim to ensure a safe and healthy working environment and to act in an ecological and sustainable manner.
Boehringer Ingelheim Office Hours 2024: Shaping the Future of Innovation in Europe
Boehringer Ingelheim is actively supporting the next generation of innovators.
Boehringer Ingelheim Awards Innovation Prize to Ablevia
Innovative solution from Ablevia for rapid and selective elimination of harmful antibodies without impediment to the immune system
Research at Regional Center Vienna
RCV is the regional affiliate of Boehringer Ingelheim and responsible for over 30 countries in Central and Eastern Europe and Central Asia.
Making sustainable medicines through eco-design
Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Interstitial Lung Diseases - Sound the ILD Alarm
Learn more about ILDs and why it's important to ‘sound the ILD alarm’ for early detection and treatment.
The domino effect of cardiovascular, renal and metabolic conditions
The domino effect of cardiovascular, renal and metabolic conditions
Testing New Treatments for NF1
The Medical University of Vienna and Boehringer Ingelheim have taken an innovative approach to the development of ways of treating NF1-associated tumors.
Veterinarians: caught between excellence and exhaustion
Many children dream of becoming a veterinarian. What happens when that dream comes true?
Embracing diversity in clinical trials: A global mandate
Have you ever wondered why medicines work differently for different people? Each patient is unique. By embracing diversity in clinical trials, we enable more equitable and inclusive healthcare.